Crinetics Pharmaceuticals, Inc.

( )
CRNX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.02%143.900.7%$893.02m
PFEPfizer Inc. 0.22%37.150.9%$765.64m
MRKMerck & Co., Inc. -0.09%78.010.7%$625.08m
BMYBristol-Myers Squibb Co. 0.03%60.001.0%$622.18m
ABBVAbbVie, Inc. 0.16%83.001.9%$592.58m
LLYEli Lilly & Co. -0.02%141.281.1%$483.68m
AZNAstraZeneca Plc 0.12%51.631.2%$202.42m
NVSNovartis AG -0.40%83.800.2%$141.45m
GSKGlaxoSmithKline Plc -0.40%35.210.2%$138.35m
NVONovo Nordisk A/S 0.18%70.980.1%$70.06m
RPRXRoyalty Pharma Plc 0.00%39.000.2%$63.66m
RGENRepligen Corp. 0.00%171.767.1%$62.43m
SNYSanofi -0.41%48.970.2%$49.77m
AMAGAMAG Pharmaceuticals, Inc. 0.00%13.6322.1%$45.03m
OPKOPKO Health, Inc. 1.80%4.2511.2%$41.24m

Company Profile

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.